A new era of healthcare is upon us. Using computational tools and integrated data, precision medicine aims to prevent and treat disease by taking into account people's individual variations in genes, environment, and lifestyle. But how do we implement precision medicine effectively, efficiently, and equitably to improve patient outcomes?

TRANSPERS provides objective evidence on payer coverage, economic value, and stakeholder decision-making to support the implementation of precision medicine into clinical care and health policy.
Research Overview:
TRANSPERS uses an integrated, interdisciplinary, and innovative approach to gather evidence about how genomic information is being translated into clinical practice and health policy. We focus on developing solutions to challenges that take into account the diverse stakeholders that are critical for successful adoption.

We explore critical questions about the implementation of precision medicine into clinical care and health policy:

- Which tests are covered by payer coverage policies and why?
- How do payers make coverage decisions, and what evidence do they need to make the most appropriate decisions?
- What is the economic value of precision medicine?
- How do patients and providers make decisions about the use of precision medicine tests?
- How can we better design policies to encourage the most effective and equitable use of these new technologies?

TRANSPERS Focuses on 3 Key Factors

TRANSPERS has been funded by the National Institutes of Health and other non-profit organizations since it was founded. The center is led by Kathryn A. Phillips Ph.D.